Belsomra (Suvorexant) Patent Expiration, LOE Window & CMS Spending

Belsomra (Suvorexant) by Merck & Co.: FDA Orange Book core substance LOE 2029-11-20 (last listed 2033-05-29), 0 AB generics, $170.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN204569 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-11-20
Last Listed Patent or Exclusivity Date2033-05-29
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$170.7M
2024 Medicare Part D Spend$150.2M
2024 Medicaid Spend$20.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.